Mosedipimod, also known as EC-18, is an immunomodulator, anti-inflammatory drug candidate. Mosedipimod is a synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Mosedipimod stimulates calcium influx into T lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T and B lymphocytes, dendritic cells (DCs) and macrophages. Therefore, mosedipimod may stimulate the immune system to target cancer cells. In addition, mosedipimod enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.
MedKoo Cat#: 561855
Name: Mosedipimod
CAS#: 221139-79-3
Chemical Formula: C39H70O6
Exact Mass: 634.5172
Molecular Weight: 634.98
Elemental Analysis: C, 73.77; H, 11.11; O, 15.12
The following data is based on the product molecular weight 634.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
